Clinical Trial Update: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine [Phase 3]

View source ↗

Summary

A long-term extension study to assess adverse events of oral atogepant tablets in pediatric participants (6 to 17 years old) with migraine, currently enrolling …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Atogepant (Atogepant)

Snippet

Sponsor: AbbVie | Conditions: Migraine Prophylaxis | Phase 3 | Status: ENROLLING_BY_INVITATION